OBJECTIVES: Pulmonary complications are common following hematopoietic stem cell transplantation. Numerous idiopathic post-transplantation pulmonary syndromes have been described. Patients at the severe end of this spectrum may present with hypoxemic respiratory failure and pulmonary infiltrates, meeting criteria for acute respiratory distress syndrome. The incidence and outcomes of acute respiratory distress syndrome in this setting are poorly characterized. DESIGN: Retrospective cohort study. SETTING: Mayo Clinic, Rochester, MN. PATIENTS: Patients undergoing autologous and allogeneic hematopoietic stem cell transplantation between January 1, 2005, and December 31, 2012. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Patients were screened for acute respiratory distress syndrome development within 1 year of hematopoietic stem cell transplantation. Acute respiratory distress syndrome adjudication was performed in accordance with the 2012 Berlin criteria. In total, 133 cases of acute respiratory distress syndrome developed in 2,635 patients undergoing hematopoietic stem cell transplantation (5.0%). Acute respiratory distress syndrome developed in 75 patients (15.6%) undergoing allogeneic hematopoietic stem cell transplantation and 58 patients (2.7%) undergoing autologous hematopoietic stem cell transplantation. Median time to acute respiratory distress syndrome development was 55.4 days (interquartile range, 15.1-139 d) in allogeneic hematopoietic stem cell transplantation and 14.2 days (interquartile range, 10.5-124 d) in autologous hematopoietic stem cell transplantation. Twenty-eight-day mortality was 46.6%. At 12 months following hematopoietic stem cell transplantation, 89 patients (66.9%) who developed acute respiratory distress syndrome had died. Only 7 of 133 acute respiratory distress syndrome cases met criteria for engraftment syndrome and 15 for diffuse alveolar hemorrhage. CONCLUSIONS: Acute respiratory distress syndrome is a frequent complication following hematopoietic stem cell transplantation, dramatically influencing patient-important outcomes. Most cases of acute respiratory distress syndrome following hematopoietic stem cell transplantation do not meet criteria for a more specific post-transplantation pulmonary syndrome. These findings highlight the need to better understand the risk factors underlying acute respiratory distress syndrome in this population, thereby facilitating the development of effective prevention strategies.
OBJECTIVES:Pulmonary complications are common following hematopoietic stem cell transplantation. Numerous idiopathic post-transplantation pulmonary syndromes have been described. Patients at the severe end of this spectrum may present with hypoxemic respiratory failure and pulmonary infiltrates, meeting criteria for acute respiratory distress syndrome. The incidence and outcomes of acute respiratory distress syndrome in this setting are poorly characterized. DESIGN: Retrospective cohort study. SETTING:Mayo Clinic, Rochester, MN. PATIENTS: Patients undergoing autologous and allogeneic hematopoietic stem cell transplantation between January 1, 2005, and December 31, 2012. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS:Patients were screened for acute respiratory distress syndrome development within 1 year of hematopoietic stem cell transplantation. Acute respiratory distress syndrome adjudication was performed in accordance with the 2012 Berlin criteria. In total, 133 cases of acute respiratory distress syndrome developed in 2,635 patients undergoing hematopoietic stem cell transplantation (5.0%). Acute respiratory distress syndrome developed in 75 patients (15.6%) undergoing allogeneic hematopoietic stem cell transplantation and 58 patients (2.7%) undergoing autologous hematopoietic stem cell transplantation. Median time to acute respiratory distress syndrome development was 55.4 days (interquartile range, 15.1-139 d) in allogeneic hematopoietic stem cell transplantation and 14.2 days (interquartile range, 10.5-124 d) in autologous hematopoietic stem cell transplantation. Twenty-eight-day mortality was 46.6%. At 12 months following hematopoietic stem cell transplantation, 89 patients (66.9%) who developed acute respiratory distress syndrome had died. Only 7 of 133 acute respiratory distress syndrome cases met criteria for engraftment syndrome and 15 for diffuse alveolar hemorrhage. CONCLUSIONS:Acute respiratory distress syndrome is a frequent complication following hematopoietic stem cell transplantation, dramatically influencing patient-important outcomes. Most cases of acute respiratory distress syndrome following hematopoietic stem cell transplantation do not meet criteria for a more specific post-transplantation pulmonary syndrome. These findings highlight the need to better understand the risk factors underlying acute respiratory distress syndrome in this population, thereby facilitating the development of effective prevention strategies.
Authors: Ognjen Gajic; Ousama Dabbagh; Pauline K Park; Adebola Adesanya; Steven Y Chang; Peter Hou; Harry Anderson; J Jason Hoth; Mark E Mikkelsen; Nina T Gentile; Michelle N Gong; Daniel Talmor; Ednan Bajwa; Timothy R Watkins; Emir Festic; Murat Yilmaz; Remzi Iscimen; David A Kaufman; Annette M Esper; Ruxana Sadikot; Ivor Douglas; Jonathan Sevransky; Michael Malinchoc Journal: Am J Respir Crit Care Med Date: 2010-08-27 Impact factor: 21.405
Authors: Alois Gratwohl; Helen Baldomero; Mahmoud Aljurf; Marcelo C Pasquini; Luis Fernando Bouzas; Ayami Yoshimi; Jeff Szer; Jeff Lipton; Alvin Schwendener; Michael Gratwohl; Karl Frauendorfer; Dietger Niederwieser; Mary Horowitz; Yoshihisa Kodera Journal: JAMA Date: 2010-04-28 Impact factor: 56.272
Authors: C Trillo-Alvarez; R Cartin-Ceba; D J Kor; M Kojicic; R Kashyap; S Thakur; L Thakur; V Herasevich; M Malinchoc; O Gajic Journal: Eur Respir J Date: 2010-06-18 Impact factor: 16.671
Authors: Erik von Elm; Douglas G Altman; Matthias Egger; Stuart J Pocock; Peter C Gøtzsche; Jan P Vandenbroucke Journal: Lancet Date: 2007-10-20 Impact factor: 79.321
Authors: Angela Panoskaltsis-Mortari; Matthias Griese; David K Madtes; John A Belperio; Imad Y Haddad; Rodney J Folz; Kenneth R Cooke Journal: Am J Respir Crit Care Med Date: 2011-05-01 Impact factor: 21.405
Authors: J S Groeger; S Lemeshow; K Price; D M Nierman; P White; J Klar; S Granovsky; D Horak; S K Kish Journal: J Clin Oncol Date: 1998-02 Impact factor: 44.544
Authors: Anas Alsara; David O Warner; Guangxi Li; Vitaly Herasevich; Ognjen Gajic; Daryl J Kor Journal: Mayo Clin Proc Date: 2011-05 Impact factor: 7.616
Authors: Ted A Gooley; Jason W Chien; Steven A Pergam; Sangeeta Hingorani; Mohamed L Sorror; Michael Boeckh; Paul J Martin; Brenda M Sandmaier; Kieren A Marr; Frederick R Appelbaum; Rainer Storb; George B McDonald Journal: N Engl J Med Date: 2010-11-25 Impact factor: 91.245
Authors: Guangxi Li; Michael Malinchoc; Rodrigo Cartin-Ceba; Chakradhar V Venkata; Daryl J Kor; Steve G Peters; Rolf D Hubmayr; Ognjen Gajic Journal: Am J Respir Crit Care Med Date: 2010-08-06 Impact factor: 21.405
Authors: Jung Yoon Choi; Hyoung Jin Kang; Kyung Taek Hong; Che Ry Hong; Yun Jeong Lee; June Dong Park; Ji Hoon Phi; Seung-Ki Kim; Kyu-Chang Wang; Il Han Kim; Sung-Hye Park; Young Hun Choi; Jung-Eun Cheon; Kyung Duk Park; Hee Young Shin Journal: Int J Clin Oncol Date: 2019-07-27 Impact factor: 3.402
Authors: Nadine A Kerr; Juan Pablo de Rivero Vaccari; Sam Abbassi; Harmanpreet Kaur; Ronald Zambrano; Shu Wu; W Dalton Dietrich; Robert W Keane Journal: J Neurotrauma Date: 2018-06-08 Impact factor: 5.269
Authors: D N O'Dwyer; A S Duvall; M Xia; T C Hoffman; K S Bloye; C A Bulte; X Zhou; S Murray; B B Moore; G A Yanik Journal: Bone Marrow Transplant Date: 2017-10-23 Impact factor: 5.483
Authors: Joshua A Englert; Michael H Cho; Andrew E Lamb; Maya Shumyatcher; Diana Barragan-Bradford; Maria C Basil; Angelica Higuera; Colleen Isabelle; Mayra Pinilla Vera; Paul B Dieffenbach; Laura E Fredenburgh; Joyce B Kang; Ami S Bhatt; Joseph H Antin; Vincent T Ho; Robert J Soiffer; Judie A Howrylak; Blanca E Himes; Rebecca M Baron Journal: Respir Res Date: 2019-01-21